Figure 6From: Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetesChange in plasma glucagon. When compared to placebo glucagon-like peptide-1 (GLP-1) caused no apparent effect on change in plasma glucagon concentrations from baseline.Back to article page